New York - Even as biologic therapies become available, there will still be a place for acitretin, methotrexate and cyclosporin-based treatment protocols, according to Mark Lebwohl, M.D.
The Weekly Roundup: April 15-19
The Cutaneous Connection: Make Data-Driven Decisions For Personalized AD Treatment
Half of Patients With Psoriasis Receiving Placebo In Clinical Trials Report Adverse Events
ReV Up Your Vitiligo Treatment Strategies
Mobile Health Technologies In Studies of Actinic Keratosis Do Not Compromise Patient Safety, Research Article Says
Brittany Scurto, PA-C: How to Discuss an Integrative Medicine Approach With Patients